Alnylam Pharmaceuticals Inc (ALNY)
Healthcare
Biotechnology
205.50 $
+0.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Alnylam Pharmaceuticals Inc (ALNY)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.6% of the shares are freely tradable; institutional investors hold 102.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
102.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
0.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
99.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
5.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
134Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 10.90 | 14,579,166 | -8.3 | 03/31/2026 |
| Capital World Investors | 8.07 | 10,802,348 | -33.7 | 03/31/2026 |
| BlackRock Inc | 7.81 | 10,444,908 | +0.4 | 03/31/2026 |
| Capital Research Global Investors | 7.08 | 9,471,181 | +39.7 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.85 | 6,491,280 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 4.73 | 6,323,752 | +34.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.44 | 5,946,706 | +0.0 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 3.88 | 5,193,324 | +78.8 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Capital Group Growth Fnd of Amer Comp | 5.71 | 7,620,583 | -5.0 | 06/30/2026 |
| American Funds Growth Fd of Amer A | 5.71 | 7,620,583 | -5.0 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.